LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

A Protein Is Unusual Tumor Suppressor

By Biotechdaily staff writers
Posted on 22 Feb 2006
Cancer researchers have shown that the tumor-suppressing protein REG-gamma activates the proteasome-mediated destruction of the protein product of the powerful oncogene steroid receptor coactivator-3 (SRC-3).

Investigators at Baylor College of Medicine (Houston, TX, USA) used RNA interference (RNAi) technology to "knockdown” the activity of REG-gamma. Their results published in the January 27, 2006, issue of Cell showed that reduction of REG-gamma activity allowed the overexpression of SRC-3 with subsequent stimulation of tumor cell growth. In vitro proteasome proteolysis assays using purified REG-gamma, SRC-3, and the 20S proteasome demonstrated that REG-gamma promoted the degradation of SRC-3 in an ubiquitin- and ATP-independent manner.

"It is another intervention point where one can now attack tumors. It is especially important for endocrine tumors such as those of the breast, prostate, ovary, and pituitary gland,” said senior author Dr. Bert O'Malley, professor of molecular and cellular biology at Baylor College of Medicine. "This is an important pathway for SRC3 degradation that has never been described. This molecule does not require ubiquitin or an energy source, it is a really strange and different molecule for that reason.”



Related Links:
Baylor College of Medicine

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Automated Immunoassay Analyzer
SuperFlex™
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test

Latest BioResearch News

Population-Scale Proteomics Study Identifies New Genetic-Protein Links
22 Feb 2006  |   BioResearch

Circulating Tumor DNA Helps Identify Targets for Personalized Immunotherapy
22 Feb 2006  |   BioResearch

Researchers Classify 108 Lysosomal Disorders in Updated Diagnostic Framework
22 Feb 2006  |   BioResearch